Clinical trials: Acquired Immune Deficiency Syndrome (AIDS)
AIDS
Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc
The objective of this study was to estimate the effects of a single dose of vardenafil on the blood pressure (BP) in subjects receiving maraviroc (MVC) (dosed to steady-state) and to assess the safety and tolerability of MVC in…
- Trial name
- NCT00853840
- Testing
- Maraviroc, Vardenafil
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV
To determine the safety and anti-HIV activity of two doses of SC-49483 in combination with zidovudine (AZT) versus AZT alone. To determine the influences of viral phenotype on the anti-HIV activity of these treatment regimens.
- Trial name
- NCT00000791
- Testing
- Glycovir, Zidovudine
- Where
- 22 sites in United States
- Volunteers
- 210 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronary Heart Disease, Heart Failure
Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 7.5 Years Follow-up
Since the introduction of antiretroviral therapy life expectancy of HIV-infected persons is rising. Different cohorts are observing an increased risk for cardiovascular diseases in this aging HIV-infected population.
- Conditions
- Coronary Heart Disease, Heart Failure, HIV, AIDS
- Trial name
- NCT01667068
- Testing
- Comprehensive non invasive cardiovascular examination
- Where
- 6 sites in Germany
- Volunteers
- 1,481 people
- Sponsor
- University Hospital, Essen
Depression, HIV
SSRI Effects on Depression and Immunity in HIV/AIDS
This is a 10 week, double-blind, placebo controlled trial to evaluate SSRI (Selective Serotonin Reuptake Inhibitor) effects for treatment of depression in HIV/AIDS with a focus on innate immunity and inflammation.
- Conditions
- Depression, HIV, AIDS
- Trial name
- NCT02620150
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- University of Pennsylvania
HIV Infections, Diarrhea
The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients
The purpose of this study is to asses whether probiotics Lactobacillus rhamnosus (GR-1) and reuteri (RC-14) are able to prevent diarrhea, delay the decline of the immune system and prevent and/or cure bacterial vaginosis among…
- Conditions
- HIV Infections, Diarrhea, Bacterial Vaginosis
- Trial name
- NCT00536848
- Testing
- Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14, Metronidazole
- Where
- Tanzania
- Volunteers
- 65 people
- Sponsor
- National Institute for Medical Research, Tanzania
Skin and Soft Tissue Infections, Hiv
ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs
Access to Syringes at Pharmacies (ASAP) is a refinement of an evidence-based, pharmacy intervention to increase pharmacy-based sales of syringes to PWID in order to reduce bloodborne illnesses among them.
- Conditions
- Skin and Soft Tissue Infections, Hiv, Hepatitis C, Bloodstream Infection
- Trial name
- ASAP (NCT05270135)
- Testing
- ASAP
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Hiv
ANRS 12415 - Quali PrEP Cambodia
Hypothesis: Hypothesis 1 : Regarding the recentness of preexposure prophylaxis (PrEP) implementation with an uptake of 20% and according to the first consultative meeting, awareness and acceptability of PrEP seems to be low in…
- Trial name
- ANRS 12415 (NCT05091489)
- Testing
- Qualitative assessment about PrEP acceptability
- Where
- Cambodia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
HIV/AIDS
Positive Affect Promotion to Empower Optimal Adherence to HIV Therapy
This study assesses the feasibility and acceptability of the APPEAL program, a 3-session intervention designed to promote positive affect among men and women living with HIV infection.
- Trial name
- NCT04035759
- Testing
- APPEAL
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- State University of New York - Downstate Medical Center
HIV Infections
A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons
To determine the safety of immunization with HIV-1 C4-V3 polyvalent peptide vaccine in HIV-infected persons. To determine the proportion of study participants immunized who develop new specificities or increased levels of…
- Trial name
- NCT00001060
- Testing
- HIV-1 C4-V3 Polyvalent Peptide Vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Filarial Infection, HIV Infections
Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis
This study, sponsored by the National Institutes of Health and the Tuberculosis Research Centre and YRG-Care in Chennai, India, will examine how treatment of lymphatic filariasis in HIV-infected patients influences the amount of…
- Trial name
- NCT00344279
- Where
- 3 sites in India
- Volunteers
- 1,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anemia, Iron-deficiency
Optimizing Iron Status While Minimizing Morbidity in HIV-infected Ugandan Children
Randomized, placebo-controlled trial of the effect of 84 days of daily iron supplementation on iron status, gut microbiome profile, infectious disease frequency, and HIV disease severity in moderately anemic [hemoglobin 9 - <11…
- Conditions
- Anemia, Iron-deficiency, Iron Deficiency Anemia, Hiv
- Trial name
- NCT03596996
- Testing
- Ferrous Sulfate
- Where
- Uganda
- Volunteers
- 200 people
- Sponsor
- University of Minnesota
HIV/AIDS, Medication Adherence
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
Introduction of antiretroviral therapy (ART) has transformed HIV-infection from a fatal to manageable disease but adherence to ART remains critical to optimize outcomes.
- Trial name
- NCT02797262
- Testing
- Proteus digital health feedback (PDHF) system
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of California, Los Angeles
Visceral Leishmaniosis, HIV-infection/Aids
Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Visceral leishmaniosis (VL) is widely reported in Ethiopia, with about 30% of cases being associated with human immunodeficiency virus (HIV).
- Trial name
- NCT01360762
- Testing
- Pentamidine
- Where
- 3 sites in Ethiopia
- Volunteers
- 74 people
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV Infections
A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine
To evaluate the clinical, immunologic, and virologic effects of oral zidovudine (AZT) plus intravenous immunoglobulin (IVIG) versus AZT plus placebo (albumin).
- Trial name
- NCT00000720
- Testing
- Globulin, Immune, Zidovudine
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Avium-intracellulare Infection, HIV Infections
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study
Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin.
- Trial name
- NCT00002080
- Testing
- Rifabutin
- Where
- United States
- Sponsor
- Pharmacia
HIV Infections
A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002
To evaluate the efficacy of AZT versus ddC in terms of survival, antiviral effects, neurological status, and health status in patients post Pneumocystis carinii pneumonia (PCP) who received long-term AZT therapy in ACTG protocol…
- Trial name
- NCT00000682
- Testing
- Zidovudine, Zalcitabine
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
Factors Associated With Late HIV Diagnosis in Grampian: an Epidemiological Study
Human immunodeficiency virus (HIV) is a major global health concern which has resulted in an estimated 39 million deaths world-wide.
- Trial name
- NCT02804724
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 124 people
- Sponsor
- University of Aberdeen
Hiv, Substance Use Disorders
PrEP at a Syringe Services Program
The purpose of this study is to see if providing participants with pre-exposure prophylaxis (PrEP) medicine right away at the IDEA Exchange will help participants remain in HIV negative.
- Trial name
- NCT04782180
- Testing
- Descovy 200Mg 25Mg Tablet, PrEP
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Miami
Human Immunodeficiency Virus, Substance Related Disorder
Trauma Intervention for Affect Regulation, AIDS, and Substances
The Purpose of this study is to see if it is possible to deliver an intervention that targets trauma, substance use, and engagement in HIV care with HIV-positive women.
- Conditions
- Human Immunodeficiency Virus, Substance Related Disorder, Post Traumatic Stress Disorder
- Trial name
- TIARAS (NCT02923141)
- Testing
- Neutral Writing, Expressive Writing, Contingency Management
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Miami
HIV - Human Immunodeficiency Virus
Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy
The purpose of this trial is to evaluate the immunomodulatory effects of glatiramer acetate (GA) in improving the recovery of CD4 T cells and the CD4/CD8 ratio in people living with HIV (PLWHIV) who have poor immune recovery and…
- Trial name
- GEODE (NCT07851337)
- Testing
- - Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml
- Volunteers
- 36 people
- Sponsor
- ANRS, Emerging Infectious Diseases
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.